| Theme | Dialysis related amyloidosis and associated bone and joint disorders | |
|---|---|---|
| Title | Dialysis-related amyloidosis : overview | |
| Publish Date | 2016/07 | |
| Author | Suguru Yamamoto | Division of Clinical Nephrology and Rheumatology, Niigata University Medical and Dental Hospital |
| [ Summary ] | It has been 30 years since β2-microglobulin was first determined to be a precursor protein associated with dialysis-related amyloidosis. Thirty years of basic research have suggested a number of biological molecules which may be related to β2-microglobulin-related amyloid fibril formation and extension in vitro. Clinically, high-flux dialysis membranes, β2-microglobulin adsorption columns, and hemodiafiltration have improved removal of circulating β2-microglobulin. Some studies have indicated a decreasing incidence of dialysis-related amyloidosis over the past 30 years. A recent report indicated a variant of β2-microglobulin as a cause of familial systemic amyloidosis. The use of antibody treatment for serum amyloid P component has been reported to reduce amyloid deposition in patients with systemic amyloidosis. Understanding of dialysis-related amyloidosis may lead to the discovery of common pathophysiologies and therapeutic strategies for treatment of various kinds of amyloidosis. | |